Maria Fankhauser, Nicole Bechmann, Michael Lauseker, Judith Goncalves, Judith Favier, Barbara Klink, Doreen William, Laura Gieldon, Julian Maurer, Gerald Spöttl, Petra Rank, Thomas Knösel, Michael Orth, Christian G Ziegler, Elke Tatjana Aristizabal Prada, German Rubinstein, Martin Fassnacht, Christine Spitzweg, Ashley B Grossman, Karel Pacak, Felix Beuschlein, Stefan R Bornstein, Graeme Eisenhofer, Christoph J Auernhammer, Martin Reincke, Svenja Nölting
There are no officially approved therapies for metastatic pheochromocytomas apart from ultratrace 131I-MIBG therapy approved only in the United States. We have, therefore, investigated the anti-tumor potential of novel molecular-targeted approaches in murine pheochromocytoma cell lines (MPC/MTT), immortalized mouse chromaffin Sdhb-/- cells, 3D-pheochromocytoma tumor models (MPC/MTT spheroids) and human pheochromocytoma primary cultures. We identified the specific PI3Kα inhibitor BYL719 and the mTORC1 inhibitor everolimus as the most effective combination in all models...
July 19, 2019: Endocrinology